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Introduction: Cyclooxygenase (COX)-2 and microsomal prosta-
glandin E synthase (mPGES)-1 have been found to be overexpressed
in non-small cell lung cancer (NSCLC). The aim of this study was
to investigate the expression profiles of COX-2 and mPGES-1 and
their correlation with the clinical characteristics and survival out-
comes in patients with resected NSCLC.
Methods/Results: Seventy-nine paired adjacent normal-tumor
matched samples were prospectively procured from patients under-
going surgery for NSCLC. The protein levels of COX-2 and
mPGES-1 were assessed by Western blot analysis. Overexpression
in the tumor sample was defined as more than twofold increase in
protein expression compared with the corresponding adjacent nor-
mal tissue. Co-overexpression of COX-2 and mPGES-1 were further
confirmed by immunohistochemistry. COX-2 was overexpressed in
58% and mPGES-1 in 70% of the tumor samples (p  0.0001).
Co-overexpression of mPGES-1 and COX-2 was noted in 43%, and
they were unrelated to each other (p 0.232). Co-overexpression of
both proteins was significantly associated with less tumor differen-
tiation (p  0.046), tumor size larger than 5 cm (p  0.038), and
worse survival status during the follow-up (p 0.036). Multivariate
analysis showed that in addition to overall stage, co-overexpression
of both proteins adversely affected the overall (hazard ratio, 2.40;
p  0.045) and disease-free survivals (hazard ratio, 2.27; p 
0.029).
Conclusions: Overexpression of either COX-2 or mPGES-1 is
common but unrelated in NSCLC. Co-overexpression of both
COX-2 and mPGES-1 adversely affects postoperative overall and
disease-free survivals.
Key Words: Non-small cell lung cancer, Cyclooxygenase-2, Mi-
crosomal prostaglandin E synthase-1, Survival.
(J Thorac Oncol. 2010;5: 1167–1174)
Lung cancer is the leading cause of cancer death amongboth men and women worldwide, and non-small cell lung
cancer (NSCLC) accounts for more than 80% of all lung
cancer. Surgery is the mainstay of treatment for early-stage
NSCLC; however, result of surgical treatment alone remains
unsatisfactory.1 It is imperative to identify biomarkers that
can predict patients’ outcome after surgery.
Epidemiologic studies have shown that long-term use
of nonsteroidal anti-inflammatory drugs decreases the risks of
several cancers, including NSCLC.2,3 Cyclooxygenase
(COX), the key enzyme in the biosynthesis of prostaglandins
(PGs), is the main target of nonsteroidal anti-inflammatory
drugs.4 Two isoforms of COX, COX-1 and COX-2, each
encoded by separate genes, have been identified. In the
biosynthesis of PGs, arachidonic acid is first mobilized from
membrane glycerophospholipids by the action of phospho-
lipase A2. The COX enzymes then catalyze the formation of
an intermediate PGG2, followed by reduction to PGH2. PGH2
is subsequently converted to several structurally related PGs,
including PGE2, PGD2, PGF2, PGI2 and thromboxane A2 by
the activity of specific PG synthases. Among the several
kinds of PGs, increased production of PGE2 has been found
in various malignancies.5,6 Many studies have indicated that
PGE2 plays a key role in carcinogenesis and cancer progres-
sion.7,8 Increased expression of COX-2 has been found in a
variety of human malignancies, including lung cancer.9,10
The PGE synthase (PGES), which catalyzes the forma-
tion of PGE2, was first identified by Jakobsson et al. in
1999.11 There are at least three PGES isoenzymes, namely the
cytosolic PGES and microsomal PGES (mPGES)-1 and
-2.12,13 Similar to COX-1, cytosolic PGES has been demon-
strated to be constitutively expressed in many tissues and
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functionally coupled with COX-1 in the maintenance of
tissue homeostasis,12 whereas mPGES-1 was found to be
inducible and act in concert with COX-2 and contribute to a
variety of physiologic and pathologic conditions, such as
fever, inflammation, and reproduction.14 Overexpression of
mPGES-1 has been shown in about 65 to 80% of patients
with NSCLC.15–17
We have previously reported that mPGES-1 overex-
pression was not significantly associated with either overall
or disease-free survival in 93 patients undergoing surgical
resection for NSCLC.15 Additionally, there was no significant
association between the expression of mPGES-1 and COX-2
in 30 cases. In this study, we have investigated the co-
overexpression of COX-2 and mPGES-1 in surgical speci-
mens prospectively procured from 79 NSCLC patients, and
elucidated its role with the clinical characteristics and sur-
vival outcome.
PATIENTS AND METHODS
Patients and Tissue Procurement
Seventy-nine patients with NSCLC who underwent
surgical resection in a tertiary medical center between March
1999 and June 2003 were enrolled in this study. The tissue
procurement protocol was approved by the institutional re-
view board, and written informed consent was obtained from
all patients. The patients included 56 (70.9%) men and 23
(29.1%) women, with a mean age of 66.9  11.2 years
(mean  standard deviation; range, 30–83 years). Tumor
histology and stages were classified according to the World
Health Organization classification and the international stag-
ing system for lung cancer.18,19 Forty-seven (59.5%) tumors
were classified as adenocarcinoma, 22 (27.8%) as squamous-
cell carcinoma, 7 (8.9%) as large-cell carcinoma, and 3
(3.8%) as pleomorphic carcinoma. Lobectomy was per-
formed in 60 (75.9%) patients, bilobectomy in 8 (10.1%),
pneumonectomy in 5 (6.3%), segmentectomy in 3 (3.8%),
and wedge resection in 3 (3.8%). Mediastinal lymph node
sampling or dissection was done for all patients, with the
mean number of removed lymph nodes being 17.8  10.4
(mean standard deviation) per patient. After the surgery, 22
(27.8%) patients received adjuvant therapy; 12 (15.2%) pa-
tients received chemotherapy, 8 (10.1%) patients received
radiotherapy, and 2 (2.5%) patients received chemoradiation
therapy. Samples from non-necrotic area of the tumor and
from adjacent nontumor tissue were obtained from at the time
of surgery. These tissues were immediately frozen in liquid
nitrogen, and stored at 80°C until analysis. After surgery,
the patients were followed up regularly with physical exam-
ination and imaging study. The study follow-up ended in
March 2006, and the mean follow-up duration was 27.2 
12.4 months (surgical mortality included; range, 0.3–47.8
months). The length of follow-up was defined as the interval
between the date of surgical resection and the date of either
death or the last follow-up. There was no difference in the
overall follow-up time between patients with co-expression
of COX-2 and mPGES-1 and patients without co-expression.
Protein Extraction and Western Blot Analysis
Protein extraction was carried out as previously de-
scribed20 with some modifications. In brief, frozen tissue was
homogenized and thawed in ice-cold radioimmunoprecipita-
tion buffer added with 100 g/ml phenylmethylsulfonyl flu-
oride, 25 g/ml aprotinin, 25 g/ml lupeptin, 10 g/ml
soybean trypsin inhibitor, and 1 mM sodium orthovandate.
The lysate was left on ice for 20 minutes and then centrifuged
at 12,000 rpm for 10 minutes. The clarified supernatant was
collected, and the protein concentration was measured
using Bio-Rad protein assay kit (Bio-Rad, Hercules, CA).
Sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis was performed as previously described.21 Fifty micro-
grams of protein from each sample was run in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis using a
Bio-Rad Mini-Protean system (Bio-Rad), with an 8% re-
solving gel and 4% stacking gel. The resolved proteins were
transferred onto Immobilon polyvinyl difluoride membranes
(Millipore Corp., Bedford, MA). Ponceau S (Sigma Chemi-
cal, St. Louis, MO) staining of the membranes was performed
to assess the equivalence of sample loading and gel transfer.
Computer densitometry was used to determine the relative
loading. The membranes were then destained by several
washes with tap water. After blocking with 5% skimmed milk
in Tris-buffered saline containing 0.1% Tween 20, the mem-
branes were incubated with rabbit anti-human mPGES-1
polyclonal antibody (1:500; Cayman Chemical, Ann Arbor,
MI) and goat anti-human COX-2 polyclonal antibody (1:
1000; Santa Cruz Biotechnology, Santa Cruz, CA), respec-
tively. The blots were then incubated with anti-rabbit horse-
radish peroxidase-conjugated secondary antibody for
mPGES-1 (1:2000; Amersham Pharmacia Biotech, Bucking-
hamshire, UK) or anti-goat horseradish peroxidase-conju-
gated secondary antibody for COX-2 (1:5000; Santa Cruz
Biotechnology). Subsequently, membranes were developed
using the Pierce SuperSignal chemiluminescent detection
reagents (Pierce Biotechnology, Rockford, IL) according to
the manufacturer’s instructions and exposed to NEN Renais-
sance x-ray film (New England Nuclear, Boston, MA) with
intensifying screens. The linear-range signal intensity of each
specific band on the fluorogram is quantitated by a densito-
metric scanning system and comparison of proteins of interest
is performed after normalization to the densitometric scan-
ning of the Ponceau S staining. The control value of Ponceau
S was assigned an arbitrary unit of 1, and the expression of
each protein was denoted as arbitrary densitometry units
(ADU) relative to the corresponding value of Ponceau S
stain. Overexpression of a specific protein was defined as
more than 100% increase of the ADU in tumor sample
compared with the nontumor sample.
Immunohistochemistry
Tissue sections (4 m) were prepared from paraffin-
embedded tumor blocks using a microtome and mounted on
Superfrost Plus slides (Dako, Kyoto, Japan). Sections were
deparaffinized in xylene, rehydrated in graded alcohol, and
washed in distilled water. Antigen retrieval was performed by
steaming the sections in 10 mM citric acid (pH  6.0) for 30
minutes. Subsequently, endogenous peroxidase activity was
Wu et al. Journal of Thoracic Oncology • Volume 5, Number 8, August 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1168
blocked with 3.0% hydrogen peroxide. The slides were
washed three times in phosphate-buffered saline (PBS) and
blocked for 20 minutes with 3% bovine serum albumin in
PBS. Tissue sections were then incubated with rabbit anti-
human mPGES-1 polyclonal antibody (Cayman Chemical) or
goat anti-human COX-2 polyclonal antibody (Santa Cruz
Biotechnology) at a 1:50 dilution for 1 hour at room temper-
ature. Control sections were incubated with preimmune se-
rum. After being washed three times with PBS, the secondary
antibody Dako Link (Dako LSAB2 kit; Dako) was applied for
20 minutes and then rinsed with Tris-buffered saline. Addi-
tional washing was followed by incubation with streptavidin
horseradish peroxidase (Dako LSAB2 kit; Dako) for 20
minutes. Immunoreactivity was visualized by incubation of
sections with 3-amino-9-ethylcarbazole (Sigma Chemical).
Subsequently, the slides were rinsed in tap water and coun-
terstained with hematoxylin. The slides were then dehydrated
with ethanol, rinsed with xylene, and mounted.
Statistical Analyses
Between paired tumor and nontumor samples, the ADU
of COX-2 and mPGES-1 protein expression were compared
using the paired Student t test. The association between the
expression of COX-2 and PGES in tumor tissue was analyzed
with Fisher’s exact test. The associations between various
clinicopathologic parameters, and any one of COX-2 over-
expression or mPGES-1 overexpression or co-expression of
both proteins were analyzed with Fisher’s exact test. All 79
subjects were included in the survival analysis. However, not
every subject had complete measurements for all variables
that included possible prognostic factors and important out-
comes. The overall survival is defined from the date of
operation to the date of death, including surgical mortality.
Disease-free survival was measured from the date of opera-
tion to the date of first documented recurrence, or to date of
last follow-up if no recurrence had occurred. Survival prob-
ability was calculated by Kaplan-Meier method. Univariate
Cox proportional hazard regression model was applied to
quantify the hazard ratio of each prognostic factor. The
prognostic factors with survival probability at a significance
level of 0.20 or less were considered in a multivariable Cox
proportional hazard regression analysis. Variable selection
with backward stepwise method was used to choose the
optimal independent prognostic factors. A p-value less than
0.05 was considered statistically significant. All the analyses
were performed with SPSS software version 13.0 (SPSS Inc.,
Chicago, IL).
RESULTS
Expression of COX-2 and mPGES-1 in NSCLC
Tumor Samples
Western blot analysis was performed in all paired
tumor and nontumor samples to assess the expression of
COX-2 and mPGES-1. A representative blot of five pairs of
FIGURE 1. Western blot analysis of cyclooxygenase
(COX)-2 and microsomal prostaglandin E synthase
(mPGES)-1 in 79 patients with tumor and nontumor
matched tissues. A, Representative Western blotting of adja-
cent normal (N)-tumor (T) matched tissues from five sub-
jects. Ponceau S staining was used as a loading control. B,
Boxplot showing the semiquantitative results of the COX-2
and mPGES-1 protein levels (in arbitrary densitometry units)
in 79 patients with normal-tumor matched tissues. The bot-
tom of each box is the 25th percentile; the top is the 75th
percentile; and the band in the middle is the 50th percen-
tile. The whiskers represent the minimum and maximum of
all the data. Paired Student t test was used to compare be-
tween tumor and nontumor samples.
TABLE 1. The Association Between COX-2 and mPGES-1
Protein Expression in 79 Paired Samplesa
Variable
mPGES-1
Overexpression
()
mPGES-1
Overexpression
() Total
COX-2
overexpression ()
34 12 46 (58%)
COX-2
overexpression ()
21 12 33 (42%)
Total 55 (70%) 24 (30%)
a P  0.232 by Fisher’s exact test (one-sided).
COX-2, cyclooxygenase-2; mPGES-1, microsomal prostaglandin E synthase-1.
Journal of Thoracic Oncology • Volume 5, Number 8, August 2010 Co-Overexpression of COX-2 and mPGES-1
Copyright © 2010 by the International Association for the Study of Lung Cancer 1169
NSCLC tumor and nontumor samples is shown in Figure 1A.
The ADU of each protein in 79 paired tumor and nontumor
tissues were depicted with box plots in Figure 1B. Both
COX-2 and mPGES-1 exhibited significant overexpression in
the tumor tissues (p  0.0001, respectively). As shown in
Table 1, COX-2 overexpression was noted in 46 samples, and
mPGES-1 overexpression was noted in 55 samples. There
were 34 (43%) samples showing co-overexpression of both
proteins. Co-overexpression of both mPGES-1 and COX-2 in
those samples were confirmed by immunohistochemistry
(Figure 2). However, there was no significant association
between the overexpression of both proteins by Fisher’s exact
test (p  0.232).
Survival Outcomes
Among the 79 patients enrolled for study, the overall
median survival was 27.7 12.4 months, with the 1-, 3- and
5-year cumulative survival rates of 84.8%, 76.2%, and
66.8%, respectively. At the last follow-up session, 54
(68.4%) patients were alive (16 patients with recurrent can-
cer); 17 (21.5%) patients died of cancer; 6 (7.6%) patients
died of surgery or other causes without evidence of tumor
recurrence; and 2 patients (2.5%) were lost to follow-up.
The relationship between the clinicopathologic param-
eters and protein expression in tumor sample is shown in
Table 2. COX-2 overexpression was significantly more often
observed in patients with tumors larger than 5 cm (p 
0.002). No significant correlations were observed between the
clinicopathologic parameters and the expression of
mPGES-1. Co-overexpression of both proteins was signifi-
cantly associated with less tumor differentiation (p  0.046),
tumor size larger than 5 cm (p  0.038), and worse survival
status during the follow-up (p  0.036).
As in Table 3, the univariate survival analysis demon-
strated that either COX-2 or mPGES-1, when analyzed sep-
arately, did not affect overall or disease-free survival. How-
ever, co-overexpression of COX-2 and mPGES-1, pathologic
assessment of primary tumor (pT), pathologic assessment of
lymph node (pN), and overall stage did have an impact on
overall and disease-free survivals.
Multivariate analysis showed co-overexpression of
both proteins and overall stage significantly affected the
overall and disease-free survivals (Table 4). A significant
difference in overall survival and disease-free survival was
observed between patients with co-overexpression of both
proteins or not (Figure 3A, p  0.045; and Figure 3B, p 
0.029, respectively).
DISCUSSION
Both COX-2 and mPGES-1 are often up-regulated in
clinical cancer samples, but the relative degrees of overex-
pression vary, suggesting that the regulation of the two
enzymes is not identical. We have previously reported that no
significant association existed between the expression of
COX-2 and mPGES-1 in 30 paired NSCLC tumor-nontumor
samples.15 In this study, we have further confirmed that there
is no significant correlation between the expressions of
mPGES-1 and COX-2 in 79 paired NSCLC samples.
Our previous study has shown that overexpression of
mPGES-1 was not a prognostic indicator in patients with re-
sected NSCLC. In this study, because of the increased sample
FIGURE 2. Representative results
of cyclooxygenase (COX)-2 (A and
C) and microsomal prostaglandin E
synthase (mPGES)-1 (B and D) ex-
pressed on tissue sections of lung
squamous-cell carcinoma (A and B)
and adenocarcinoma (C and D) by
immunohistochemistry. If Western
blotting results showed co-expres-
sion of COX-2 and mPGES-1, immu-
nohistochemistry was performed to
confirm their localizations. Diffuse
cytoplasmic immunoreactivity for
COX-2 and mPGES-1 were observed
in the cancer cells. Brown indicates
positive staining of COX-2 and
mPGES-1; blue indicates counter-
staining with hematoxylin (original
magnification, 200).
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size, we were able to explore and compare clinicopathologic
parameters in patients with and without co-overexpression
of COX-2 and mPGES-1. Moreover, we have used West-
ern blot analysis to quantitate the protein expression and
immunohistochemical study to confirm the co-overexpres-
sion of both proteins. Co-overexpression of both COX-2
and mPGES-1 proteins was associated with worse clinical
outcome in terms of overall and disease-free survivals.
Many studies, including our previous report, have
shown that mPGES-1 is overexpressed in NSCLC.15,17,22
TABLE 2. Relationship Between the Clinicopathologic Parameters and COX-2 and mPGES-1 Protein Expression
COX-2
Overexpression
mPGES-1
Overexpression
Overexpression
of Both COX-2
and mPGES-1
Yes No pa Yes No pa Yes No pa
Age 0.356 0.565 0.522
65 yr 29 23 36 16 22 30
65 yr 17 10 19 8 12 15
Sexa 0.481 0.214 0.380
Male 32 24 37 19 23 33
Female 14 9 18 5 11 12
Smoking index 0.506 0.430 0.522
20 pack-year 19 14 22 11 20 25
20 pack-year 27 18 32 13 14 19
Histologic type 0.151 0.463 0.424
Squamous cell 15 7 14 8 11 11
Adenocarcinoma 26 21 35 12 18 29
Large cell 4 3 5 2 4 3
Other cell types 1 2 1 2 1 2
Differentiation 0.276 0.096 0.046
Well 0 4 3 1 0 4
Moderate 32 18 38 12 26 24
Poor 13 10 13 10 7 16
Angiolymphatic invasion 0.071 0.281 0.310
Yes 19 7 17 9 21 30
No 27 24 38 13 13 13
Tumor size 0.002 0.467 0.038
5 cm 18 3 14 7 13 37
5 cm 28 30 41 17 21 8
pN status 0.135 0.415 0.055
Positive 19 9 19 9 16 12
Negative 25 23 35 13 17 31
pM status 0.300 0.482 0.368
Positive 4 1 3 2 31 43
Negative 42 32 52 22 3 2
Pathologic stage 0.363 0.344 0.420
Stage I 20 20 29 11 14 26
Stage II 9 3 6 6 5 7
Stage III 13 9 17 5 12 10
Stage IV 4 1 3 2 3 2
Adjuvant therapy 0.565 0.324 0.509
Yes 13 9 14 8 9 13
No 33 24 41 16 25 32
Tumor recurrence 0.076 0.535 0.077
Yes 21 11 22 10 17 29
No 22 22 31 13 15 15
Follow-up status 0.145 0.598 0.036
Dead 16 7 16 7 14 9
Alive 30 26 39 17 20 36
a The p values were calculated by Fisher’s exact test.
COX-2, cyclooxygenase-2; mPGES-1, microsomal prostaglandin E synthase-1; pN, pathologic assessment of lymph node; pM, pathologic assessment of distant metastasis.
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However, expression of mPGES-1 has been demonstrated in
bronchial epithelial cells in clinical specimen by immunohis-
tochemical study.17 In transgenic mice experiment, overex-
pression of mPGES-1 in bronchial epithelial cells did not
lead to lung tumorigenesis.23 Interestingly, tumor necrosis
factor- induced mPGES-1 in NSCLC cell lines, but not in
bronchial epithelial cell line.22 Martey et al.24 have shown
that cigarette smoke induced the expression of COX-2 and
mPGES-1 in human lung fibroblasts. Therefore, the ex-
pression of mPGES-1 in lung tissues could be related to
cellular transformation, cytokine stimulation, and inflam-
matory process.
Yoshimatsu et al.16 observed marked differences in the
extent of mPGES-1 and COX-2 expression in individual
paired samples from NSCLC patients. In NSCLC cell lines,
treatment with cytokines, such as IL-4 and tumor necrosis
factor-, has shown to cause differential expression between
COX-2 and mPGES-1.16,25 Lack of correlation or marked
difference between mPGES-1 and COX-2 expression in clin-
ical tumor samples has also been demonstrated in breast and
colon cancers.22,26 Similar finding on lack of coupling of
mPGES-1 and COX-2 expression has been identified in brain
and chondrocytes.27,28
Murakami et al.29 showed that cells co-expressing
COX-2 and mPGES grew faster, produced more PGE2, and
exhibited aberrant morphology compared with cells in which
either COX-2 or mPGES overexpressed. In a study investi-
gating markers involved in PG biosynthetic pathway, it has
been shown that COX-2, mPGES, and other markers may act
synergistically and promote tumor metastasis and angiogen-
esis in patients with NSCLC.30 It is plausible that co-overex-
pression of both proteins leads to higher level of PGE2 and
cellular addiction, and ultimately makes cancer cell more
aggressive in metastasis and invasion.
In an exploratory analysis with complementary DNA
microarray, we have preliminarily identified no significantly
shared expression patterns between overexpression of COX-2
and mPGES-1 (data not shown). Additionally, we have iden-
tified different genetic profiles responsible for the overexpres-
sion of COX-2 and mPGES-1 in NSCLC. Further study is in
progress to characterize novel markers identified from mi-
croarray analysis and study the roles of these markers in the
mPGES-1- and COX-2-related carcinogenesis and drug-re-
sistant mechanism.
The surgical treatment of early-stage NSCLC remains
unsatisfactory, with 5-year survival rates for pathologic
stages II and I disease ranging from 39 to 67%.1 In patients
with resected stage II or III NSCLC, adjuvant chemotherapy
with vinorelbine and cisplatin can provide approximately 8 to
15% survival benefit at 5 years.31,32 The use of adjuvant
chemotherapy in stage I NSCLC remains controversial. Iden-
tification and validation of prognostic and predictive markers
TABLE 3. Univariate Cox Proportional Hazards Model for Survival Analysis
Variable
Overall Survival Disease-Free Survival
HR 95% CI p HR 95% CI p
COX-2 overexpression ( vs. ) 1.752 0.720–4.260 0.216 1.703 0.824–3.517 0.150
mPGES-1 overexpression ( vs. ) 1.184 0.484–2.894 0.711 1.251 0.591–2.651 0.558
Co-expression COX-2 and mPGES-1 2.612 1.125–6.064 0.025 2.385 1.190–4.782 0.014
Age (65 vs. 65) 2.778 0.944–8.179 0.064 0.933 0.455–1.912 0.849
Smoking index (20 vs. 20) 1.921 0.841–4.391 0.121 0.812 0.403–1.636 0.560
Sex (female vs. male) 0.783 0.308–1.989 0.607 1.415 0.685–2.924 0.349
Differentiation gradea (1b) 1.930 0.931–4.083 0.085 1.156 0.626–2.134 0.644
Angiolymphatic invasion ( vs. ) 2.095 0.922–4.460 0.077 1.694 0.835–3.435 0.144
Adjuvant therapy (yes vs. no) 1.052 0.433–2.560 0.910 1.463 0.718–2.298 0.294
pT stagea (1b) 1.619 1.063–2.464 0.025 1.812 1.257–2.612 0.001
pN stagea (1b) 2.226 1.452–3.414 0.001 2.214 1.488–3.293 0.001
Overall stagea (1b) 2.005 1.346–2.985 0.001 2.128 1.517–2.965 0.001
a Differentiation grade, pT, pN, and overall stage were assessed as continuous variables.
b Scoring was assessed for each unit increase.
COX-2, cyclooxygenase-2; mPGES-1, microsomal prostaglandin E synthase-1; HR, hazard ratio; CI, confidence interval.
TABLE 4. Multivariate Cox Proportional Hazards Model for Survival Analysis
Variable
Overall Survival Disease-Free Survival
HR 95% CI p HR 95% CI P
Co-expression of COX-2 and
mPGES-1
2.399 1.019–5.651 0.045 2.268 1.089–4.722 0.029
Overall stagea (1b) 1.971 1.310–2.966 0.001 2.094 1.451–3.022 0.001
a Overall stage was assessed as continuous variable.
b Scoring was assessed for each unit increase.
COX-2, cyclooxygenase-2; mPGES-1, microsomal prostaglandin E synthase-1; HR, hazard ratio; CI, confidence interval.
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for patients with resected NSCLC are currently under active
investigation.33 Prognostic markers can be used to select
patients with increased risk of recurrence who may derive
more benefit from adjuvant treatment. Predictive markers
can be used to select agents to which patients’ tumors are
most likely to respond. Many prognostic markers have
been investigated in NSCLC, including k-ras mutation,
p53 mutation, excision repair cross-complementation
group 1 (ERCC1), ribonucleotide reductase subunit M1
(RRM1) expression, gene-expression array, and single
nucleotide polymorphisms.34–39
Although both COX-2 and mPGES-1 are frequently
overexpressed in NSCLC, the prognostic value of either
COX-2 or mPGES-1 remains to be determined. A meta-
analysis of 10 studies involving more than 1200 patients has
shown that only in patients with stage I NSCLC, COX-2
overexpression is associated with reduced survival (combined
hazard ratio, 1.64; 95% confidence interval, 1.21–2.24).40
Increased COX-2 expression leading to elevated PGE2 level
has been demonstrated in patients receiving chemotherapy for
NSCLC.41 Inhibition of COX-2 with celecoxib, when given
concurrently with chemotherapy, attenuated the surge of
PGE2 level in lung tumors and enhanced the response of
preoperative paclitaxel and carboplatin chemotherapy in ear-
ly-stage NSCLC.42 In Cancer and Leukemia Group B Trial
30203, Edelman et al.43 have demonstrated in patients with
advanced NSCLC that chemotherapy plus COX-2 inhibitor
therapy can improve the survival in patients with tumors
overexpressing COX-2, compared with chemotherapy alone.
In this study of 79 patients receiving surgery for NSCLC,
multivariate analysis has shown that, in addition to overall
stage, co-overexpression of COX-2 and mPGES-1 adversely
affected the overall and disease-free survivals. The prognos-
tic and predictive roles of COX-2 and mPGES-1 co-expres-
sion should be further explored in patients receiving postop-
erative chemotherapy in conjunction with inhibition of
COX-2 or PGE2.
In conclusion, we have shown that there in no associ-
ation between the overexpression of COX-2 and mPGES-1 in
NSCLC. Co-overexpression of both COX-2 and mPGES-1
adversely affects the overall and disease-free survivals in
patients receiving surgery for NSCLC. The limitations of our
findings are mainly attributed to the heterogeneous patient
population in terms of stages (stage I, 40; stage II, 12; stage
III, 21; and stage IV, 5 patients), histologic types (adenocar-
cinoma, 47; squamous cell, 22; large cell, 7; and other cell
type, 3 patients), and adjuvant therapy (observation, 57;
chemotherapy, 12; radiotherapy, 8; and chemoradiotherapy, 2
patients). Our finding can be used to identify patients at risk
after surgery for NSCLC, and to develop novel therapeutic
strategies to improve outcome. We are planning to incorpo-
rate this finding with other biomarkers, such as expression of
ERCC1 and RRM1 to design novel adjuvant treatment study
for patients with resected early-stage NSCLC.
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